{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:42:06Z","timestamp":1792280526035,"version":"4.4.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.clgc.2026.102684","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:31:01Z","timestamp":1790098261000},"page":"102684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Severe Cytopenias Following Radioligand Therapy: A Real-World Analysis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-4290-0645","authenticated-orcid":false,"given":"Robert","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8694-1918","authenticated-orcid":false,"given":"Benyamin","family":"Yaniv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3965-3394","authenticated-orcid":false,"given":"Petros","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mrinal M.","family":"Patnaik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shyam A.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9996-2012","authenticated-orcid":false,"given":"Kriti","family":"Mittal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2026.102684_bib0001","unstructured":"Institute NC. Radiopharmaceuticals: Radiation Therapy Enters the Molecular Age. Available at: https:\/\/www.cancer.gov\/news-events\/cancer-currents-blog\/2020\/radiopharmaceuticals-cancer-radiation-therapy. Accessed: April 17, 2026."},{"issue":"1","key":"10.1016\/j.clgc.2026.102684_bib0002","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1158\/1078-0432.CCR-13-2665","article-title":"Radium Ra 223 dichloride injection: U.S. Food and Drug Administration drug approval summary","volume":"20","author":"Kluetz","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.clgc.2026.102684_bib0003","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","article-title":"FDA approval summary: Lutetium Lu 177 vipivotide tetraxetan for patients with metastatic castration-resistant prostate cancer","volume":"29","author":"Fallah","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"12","key":"10.1016\/j.clgc.2026.102684_bib0004","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41585-019-0251-x","article-title":"Radium-223 mechanism of action: implications for use in treatment combinations","volume":"16","author":"Morris","year":"2019","journal-title":"Nat Rev Urol"},{"issue":"12","key":"10.1016\/j.clgc.2026.102684_bib0005","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clgc.2026.102684_bib0006","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter Radium-223 and survival in metastatic prostate Cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N EnglJ Med"},{"key":"10.1016\/j.clgc.2026.102684_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2025.101269","article-title":"Radiotherapeutics, clonal hematopoiesis, and risk of hematologic malignancies: the good, the bad, the ugly","volume":"70","author":"Marshall","year":"2025","journal-title":"Blood Rev"},{"issue":"9","key":"10.1016\/j.clgc.2026.102684_bib0008","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.3324\/haematol.2024.286808","article-title":"Hematologic dysfunction and myeloid neoplasm risk in patients treated with lutetium-177 prostate-specific antigen membrane therapy","volume":"110","author":"Kusne","year":"2025","journal-title":"Haematologica"},{"issue":"12","key":"10.1016\/j.clgc.2026.102684_bib0009","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.2967\/jnumed.123.266125","article-title":"(177)Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer and Prior (223)Ra (RALU Study)","volume":"64","author":"Rahbar","year":"2023","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.clgc.2026.102684_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102260","article-title":"Safety and efficacy of (177)Lu-PSMA therapy following (223)Radium treatment: a retrospective multinational real-world analysis","volume":"23","author":"Giannini","year":"2025","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102684_bib0011","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1007\/s00259-025-07256-5","article-title":"Cancer-control outcomes of Radium- 223-pretreated lutetium- 177-PSMA radioligand vs. Radium- 223-na\u00efve mCRPC patients","volume":"52","author":"Wenzel","year":"2025","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"10.1016\/j.clgc.2026.102684_bib0012","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.prnil.2018.08.001","article-title":"Hematologic toxicity of radium-223 in elderly patients with metastatic castration resistant prostate cancer: a real-life experience","volume":"7","author":"Costa","year":"2019","journal-title":"Prostate Int"},{"issue":"9","key":"10.1016\/j.clgc.2026.102684_bib0013","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/j.annonc.2025.05.011","article-title":"Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333\/PEACE-3 trial","volume":"36","author":"Tombal","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2026.102684_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.101993","article-title":"Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer","volume":"60","author":"Higano","year":"2023","journal-title":"eClinicalMedicine"},{"issue":"10459","key":"10.1016\/j.clgc.2026.102684_bib0015","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177-Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.clgc.2026.102684_bib0016","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"177-Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2026.102684_bib0017","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13550-021-00805-7","article-title":"Hematologic safety of (177)Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer","volume":"11","author":"Groener","year":"2021","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.clgc.2026.102684_bib0018","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-25-4001","article-title":"Clonal hematopoiesis after 177Lu-PSMA-617 radioligand therapy in prostate cancer","author":"Munzur","year":"2026","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.clgc.2026.102684_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2023.107434","article-title":"Spectrum of therapy-related clonal cytopenias and neoplasms after exposure to Lutetium-177-Dotatate","volume":"136","author":"Pritzl","year":"2024","journal-title":"Leuk Res"},{"issue":"3","key":"10.1016\/j.clgc.2026.102684_bib0020","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.eururo.2017.06.021","article-title":"Three-year safety of Radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases from phase 3 randomized alpharadin in symptomatic prostate cancer trial","volume":"73","author":"Parker","year":"2018","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.clgc.2026.102684_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2026.102552","article-title":"LuRa: efficacy and safety of Radium-223 following [177Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer","volume":"24","author":"Zarka","year":"2026","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"10.1016\/j.clgc.2026.102684_bib0022","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/nrc1735","article-title":"Radiation and the microenvironment \u2013 tumorigenesis and therapy","volume":"5","author":"Barcellos-Hoff","year":"2005","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.clgc.2026.102684_bib0023","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-00229-2","article-title":"DNA damage response of haematopoietic stem and progenitor cells to high-LET neutron irradiation","volume":"11","author":"Engelbrecht","year":"2021","journal-title":"Sci Rep"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001849?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767326001849?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T23:38:51Z","timestamp":1792280331000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767326001849"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":23,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S1558767326001849"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102684","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Severe Cytopenias Following Radioligand Therapy: A Real-World Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2026.102684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102684"}}